Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CardioComm Solutions Inc V.EKG

Alternate Symbol(s):  EKGGF

CardioComm Solutions, Inc. is a global medical provider of consumer heart monitoring and medical electrocardiogram (ECG) software solutions. The Company’s technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. It develops advanced software, hardware and core laboratory reading services related to ECG and ambulatory arrhythmia monitoring systems for medical and consumer markets globally. Its Global ECG Management Solutions (GEMS) and GlobalCardio (Cloud based GEMS) products are licensed worldwide to hospitals, ECG commercial reading services and physicians. The Company is also engaged in manufacturing, marketing, and sales of personal ECG monitors direct to consumers. The products are marketed under the HeartCheck brand. It has developed compatibility of the HeartCheck device to its GEMS and GlobalCardio based software to enable use of the device for remote ECG/arrhythmia monitoring services.


TSXV:EKG - Post by User

Bullboard Posts
Post by fjrmotoon Nov 16, 2012 11:58am
110 Views
Post# 20610204

screening results for AF

screening results for AF

"The clinical relevance of random, single assessment, population arrhythmia screening was demonstrated"

"The project demonstrates the Heartcheck ECG monitor provides an easy and efficient Arrythmia screening tool"

The findings from this project demonstrate the benefits of expanded large scale screenings of this type, so imagine a global campaign of national campaigns with several million screenings at $12.50 per report. If the Nr from Oct. 22, 2012 is read from this point of view, the revenue could be staggering over time.

Bullboard Posts